Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

Carrie Sailer, Spotswood L. Spruance, Christopher M. Hull

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalVirus Adaptation and Treatment
Volume3
Issue number1
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Herpes Labialis
Acyclovir
Hydrocortisone
Herpes Simplex
Antiviral Agents
Adrenal Cortex Hormones
Therapeutics
Placebos
Safety
Infection

Keywords

  • Acyclovir
  • Herpes labialis
  • Herpes simplex virus
  • HSV
  • Hydrocortisone
  • ME-609
  • Xerclear
  • Xerese

ASJC Scopus subject areas

  • Virology
  • Immunology
  • Infectious Diseases

Cite this

Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores. / Sailer, Carrie; Spruance, Spotswood L.; Hull, Christopher M.

In: Virus Adaptation and Treatment, Vol. 3, No. 1, 2011, p. 1-6.

Research output: Contribution to journalArticle

Sailer, Carrie ; Spruance, Spotswood L. ; Hull, Christopher M. / Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores. In: Virus Adaptation and Treatment. 2011 ; Vol. 3, No. 1. pp. 1-6.
@article{5af6eb79e59848f991a8fd78de349b7e,
title = "Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores",
abstract = "Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5{\%} acyclovir-1{\%} hydrocortisone cream (Xerese™[US], Xerclear{\circledR}[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5{\%} acyclovir-1{\%} hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle",
keywords = "Acyclovir, Herpes labialis, Herpes simplex virus, HSV, Hydrocortisone, ME-609, Xerclear, Xerese",
author = "Carrie Sailer and Spruance, {Spotswood L.} and Hull, {Christopher M.}",
year = "2011",
doi = "10.2147/VAAT.S7748",
language = "English (US)",
volume = "3",
pages = "1--6",
journal = "Virus Adaptation and Treatment",
issn = "1179-1624",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores

AU - Sailer, Carrie

AU - Spruance, Spotswood L.

AU - Hull, Christopher M.

PY - 2011

Y1 - 2011

N2 - Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

AB - Current antiviral therapies for herpes simplex labialis primarily reduce healing time. Since the host immune response also plays a role in both controlling recurrent infection as well as producing clinical symptoms, new studies are showing efficacy using topical corticosteroids. This review will evaluate the safety and efficacy of 5% acyclovir-1% hydrocortisone cream (Xerese™[US], Xerclear®[Europe]) for treatment of patients with herpes simplex labialis. A large, randomized, double-blind, placebo-controlled study recently demonstrated that treatment with 5% acyclovir-1% hydrocortisone cream significantly decreased the percentage of ulcerative lesions, reduced lesion healing time, and decreased mean lesion area compared with both topical acyclovir alone and vehicle

KW - Acyclovir

KW - Herpes labialis

KW - Herpes simplex virus

KW - HSV

KW - Hydrocortisone

KW - ME-609

KW - Xerclear

KW - Xerese

UR - http://www.scopus.com/inward/record.url?scp=79952930419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952930419&partnerID=8YFLogxK

U2 - 10.2147/VAAT.S7748

DO - 10.2147/VAAT.S7748

M3 - Article

VL - 3

SP - 1

EP - 6

JO - Virus Adaptation and Treatment

JF - Virus Adaptation and Treatment

SN - 1179-1624

IS - 1

ER -